Jaundice Clinical Trials

Find Jaundice Clinical Trials Near You

Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• History of liver cirrhosis

• Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital

Locations
United States
Utah
University of Utah Hospital
RECRUITING
Salt Lake City
Contact Information
Primary
Andrea T White, PhD
andrea.white@hsc.utah.edu
8015817818
Time Frame
Start Date: 2026-06-03
Estimated Completion Date: 2029-03-31
Participants
Target number of participants: 500
Treatments
Experimental: Bumetanide
Experimental: Furosemide
Sponsors
Leads: Stacy Johnson

This content was sourced from clinicaltrials.gov